Cytochrome P450 and ischemic heart disease: Current concepts and future directions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 2, 2014, Pages 191-213

  Rowland, Andrew ^a   Mangoni, Arduino A ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Cytochrome P450; Drug metabolism; Ischemic heart disease; Myocardial infarction; Polymorphisms; Vascular homeostasis

Indexed keywords

BILE ACID; CARDIOVASCULAR AGENT; CHOLESTEROL; CYTOCHROME P450; FATTY ACID; ICOSANOID; STEROID HORMONE; VITAMIN;

ARTERY TONE; BIOTRANSFORMATION; BLOOD PRESSURE REGULATION; DRUG METABOLISM; ENZYME LOCALIZATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PHARMACOGENETICS; REPERFUSION INJURY; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; FORECASTING; HUMANS; KIDNEY; MYOCARDIAL ISCHEMIA; MYOCARDIUM;

EID: 84892692917     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.859675     Document Type: Review

References (172)

1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380: 2197-223
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209
3. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010;121: 1768-77
4. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115: 949-52
5. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30: 11-21
6. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302: 49-57
7. Sue Masters B, Marohnic CC. Cytochromes P450-a family of proteins and scientists-understanding their relationships. Drug Metab Rev 2006;38: 209-25
8. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3: 561-97
9. Delozier TC, Kissling GE, Coulter SJ, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 2007;35: 682-8
10. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003;4: 73-84
11. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010;125: 446-63
12. Sato M, Yokoyama U, Fujita T, et al. The roles of cytochrome p450 in ischemic heart disease. Curr Drug Metab 2011;12: 526-32
13. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111: 3481-8
14. Hasemann CA, Kurumbail RG, Boddupalli SS, et al. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995;3: 41-62
15. Myasoedova KN. New findings in studies of cytochromes P450. Biochemistry Biokhimiia 2008;73: 965-9
16. Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 2008;9: 129-43
17. Stegeman JJ, Woodin BR, Klotz AV, et al. Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish Stenotomus chrysops. Mol Pharmacol 1982;21: 517-26
18. Nishimura M, Yaguti H, Yoshitsugu H, et al. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003;123: 369-75
19. Wu S, Chen W, Murphy E, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997;272: 12551-9
20. Bieche I, Narjoz C, Asselah T, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP) 1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007;17: 731-42
21. Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000;355: 979-83
22. Minamiyama Y, Takemura S, Akiyama T, et al. Isoforms of cytochrome P450 on organic nitratederived nitric oxide release in human heart vessels. FEBS Lett 1999;452: 165-9
23. Choudhary D, Jansson I, Schenkman JB, et al. Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch Biochem Biophys 2003;414: 91-100
24. Karlgren M, Backlund M, Johansson I, et al. Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. Biochem Biophys Res Commun 2004;315: 679-85
25. Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 2006;112: 564-87
26. Bauersachs J, Christ M, Ertl G, et al. Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc Res 2002;54: 669-75
27. Yu Z, Huse LM, Adler P, et al. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 2000;57: 1011-20
28. Young MJ, Clyne CD, Cole TJ, et al. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001;86: 5121-6
29. Oyekan AO, McAward K, Conetta J, et al. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am J Physiol 1999;276:R766-75
30. Wu S, Moomaw CR, Tomer KB, et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996;271: 3460-8
31. Fleming I, Michaelis UR, Bredenkotter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001;88: 44-51
32. Knights KM, Rowland A, Miners JO. Renal drug metabolism in humans: The potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 2013;76(4): 587-602
33. Baker JR, Satarug S, Reilly PE, et al. Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples. Biochem Pharmacol 2001;62: 713-21
34. Amet Y, Berthou F, Fournier G, et al. Cytochrome P450 4A and 2E1 expression in human kidney microsomes. Biochem Pharmacol 1997;53: 765-71
35. Baker JR, Edwards RJ, Lasker JM, et al. Renal and hepatic accumulation of cadmium and lead in the expression of CYP4F2 and CYP2E1. Toxicol Lett 2005;159: 182-91
36. Lasker JM, Chen WB, Wolf I, et al. Formation of 20- hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000;275: 4118-26
37. Enayetallah AE, French RA, Thibodeau MS, et al. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004;52: 447-54
38. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996;50: 52-9
39. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360: 1155-62
40. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 2001;89: 753-62
41. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 2008;18: 20-5
42. Kroetz DL, Zeldin DC. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 2002;13: 273-83
43. Jenkins CM, Cedars A, Gross RW. Eicosanoid signalling pathways in the heart. Cardiovasc Res 2009;82: 240-9
44. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000;41: 163-81
45. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 2010;48: 331-41
46. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 2004;49: 525-33
47. Hermann M, Hellermann JP, Quitzau K, et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE Trials. Atherosclerosis 2009;207: 476-9
48. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenasederived eicosanoids. Arch Biochem Biophys 2005;433: 413-20
49. Campbell WB, Gebremedhin D, Pratt PF, et al. Identification of epoxyeicosatrienoic acids as endotheliumderived hyperpolarizing factors. Circ Res 1996;78: 415-23
50. Graber MN, Alfonso A, Gill DL. Recovery of Ca2+ pools and growth in Ca2+ pool-depleted cells is mediated by specific epoxyeicosatrienoic acids derived from arachidonic acid. J Biol Chem 1997;272: 29546-53
51. Graier WF, Simecek S, Sturek M. Cytochrome P450 mono-oxygenaseregulated signalling of Ca2+ entry in human and bovine endothelial cells. J Physiol 1995;482(Pt 2): 259-74
52. Harder DR, Lange AR, Gebremedhin D, et al. Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J Vasc Res 1997;34: 237-43
53. Williams JM, Sarkis A, Lopez B, et al. Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension 2007;49: 687-94
54. Beyer AM, Gutterman DD. Regulation of the human coronary microcirculation. J Mol Cell Cardiol 2012;52: 814-21
55. Chilian WM, Dellsperger KC, Layne SM, et al. Effects of atherosclerosis on the coronary microcirculation. Am J Physiol 1990;258:H529-39
56. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12: 383-9
57. Conway DE, Sakurai Y, Weiss D, et al. Expression of CYP1A1 and CYP1B1 in human endothelial cells: regulation by fluid shear stress. Cardiovasc Res 2009;81: 669-77
58. Fisslthaler B, Hinsch N, Chataigneau T, et al. Nifedipine increases cytochrome P4502C expression and endotheliumderived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 2000;36: 270-5
59. Weintraub NL, Fang X, Kaduce TL, et al. Potentiation of endothelium- dependent relaxation by epoxyeicosatrienoic acids. Circ Res 1997;81: 258-67
60. Hecker M, Bara AT, Bauersachs J, et al. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 1994;481(Pt 2): 407-14
61. Miura H, Gutterman DD. Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca2+-activated K+ channels. Circ Res 1998;83: 501-7
62. Bauersachs J, Hecker M, Busse R. Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation. Br J Pharmacol 1994;113: 1548-53
63. Oltman CL, Weintraub NL, VanRollins M, et al. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 1998;83: 932-9
64. Carroll MA, Balazy M, Margiotta P, et al. Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol 1996;271:R863-9
65. Hercule HC, Oyekan AO. Cytochrome P450 omega/omega-1 hydroxylasederived eicosanoids contribute to endothelin(A) and endothelin(B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J Pharmacol Exp Ther 2000;292: 1153-60
66. MaassenVanDenBrink A, de Vries R, Saxena PR, et al. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res 1999;44: 407-15
67. Teerlink JR, Breu V, Sprecher U, et al. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 1994;74: 105-14
68. Schwartzman M, Ferreri NR, Carroll MA, et al. Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase. Nature 1985;314: 620-2
69. Nowicki S, Chen SL, Aizman O, et al. 20-Hydroxyeicosa-tetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+,K+- ATPase. J Clin Invest 1997;99: 1224-30
70. Randriamboavonjy V, Kiss L, Falck JR, et al. The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation. Cardiovasc Res 2005;65: 487-94
71. Stadler J, Trockfeld J, Schmalix WA, et al. Inhibition of cytochromes P4501A by nitric oxide. Proc Natl Acad Sci U S A 1994;91: 3559-63
72. Nishikawa Y, Stepp DW, Chilian WM. In vivo location and mechanism of EDHF-mediated vasodilation in canine coronary microcirculation. Am J Physiol 1999;277:H1252-9
73. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109:III27-32
74. Nakashima Y, Kawashima T, Nandate H, et al. Sustained-release nifedipine (nifedipine-L) suppresses plasma thromboxane B2 and 6-keto prostaglandin F1 alpha in both young male smokers and nonsmokers. Am Heart J 1990;119: 1267-73
75. Phillips DI, Syddall HE, Cooper C, et al. Association of adult height and leg length with fasting plasma cortisol concentrations: evidence for an effect of normal variation in adrenocortical activity on growth. Am J Hum Biol 2008;20: 712-15
76. Ferguson SS, Chen Y, LeCluyse EL, et al. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 2005;68: 747-57
77. Gerbal-Chaloin S, Daujat M, Pascussi JM, et al. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002;277: 209-17
78. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 2003;23: 1444-8
79. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98: 1487-94
80. Thum T, Borlak J. Mechanistic role of cytochrome P450 monooxygenases in oxidized low-density lipoprotein-induced vascular injury: therapy through LOX-1 receptor antagonism? Circ Res 2004;94:e1-13
81. Quyyumi AA, Dakak N, Andrews NP, et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995;92: 320-6
82. Lamping KG, Wess J, Cui Y, et al. Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 2004;24: 1253-8
83. Ren LM, Nakane T, Chiba S. Muscarinic receptor subtypes mediating vasodilation and vasoconstriction in isolated, perfused simian coronary arteries. J Cardiovasc Pharmacol 1993;22: 841-6
84. Gainer JV, Bellamine A, Dawson EP, et al. Functional variant of CYP4A11 20- hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005;111: 63-9
85. Theken KN, Schuck RN, Edin ML, et al. Evaluation of cytochrome P450- derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 2012;222: 530-6
86. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127: 529-55
87. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 2005;14: 170-5
88. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-35
89. Suzuki S, Oguro A, Osada-Oka M, et al. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J Pharmacol Sci 2008;108: 79-88
90. Motoki A, Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemiareperfusion injury in vivo. Am J Physiol Heart and Circ Physiol 2008;295:H2128-34
91. Nithipatikom K, Moore JM, Isbell MA, et al. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart and Circ Physiol 2006;291:H537-42
92. Gross GJ, Hsu A, Falck JR, et al. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol 2007;42: 687-91
93. Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006;99: 442-50
94. Moffat MP, Ward CA, Bend JR, et al. Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes. Am J Physiol 1993;264:H1154-60
95. Rastaldo R, Paolocci N, Chiribiri A, et al. Cytochrome P-450 metabolite of arachidonic acid mediates bradykinininduced negative inotropic effect. Am J Physiol Heart Circ Physiol 2001;280:H2823-32
96. Moran JH, Weise R, Schnellmann RG, et al. Cytotoxicity of linoleic acid diols to renal proximal tubular cells. Toxicol Appl Pharmacol 1997;146: 53-9
97. Siegfried MR, Aoki N, Lefer AM, et al. Direct cardiovascular actions of two metabolites of linoleic acid. Life Sci 1990;46: 427-33
98. Sugiyama S, Hayakawa M, Nagai S, et al. Leukotoxin, 9, 10-epoxy-12- octadecenoate, causes cardiac failure in dogs. Life Sci 1987;40: 225-31
99. Ma YH, Gebremedhin D, Schwartzman ML, et al. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res 1993;72: 126-36
100. Nithipatikom K, Gross ER, Endsley MP, et al. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res 2004;95:e65-71
101. Nithipatikom K, DiCamelli RF, Kohler S, et al. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem 2001;292: 115-24
102. Granville DJ, Tashakkor B, Takeuchi C, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci U S A 2004;101: 1321-6
103. Hunter AL, Bai N, Laher I, et al. Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction. Vascul Pharmacol 2005;43: 213-19
104. Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004;95: 506-14
105. Gross GJ, Nithipatikom K. Soluble epoxide hydrolase: a new target for cardioprotection. Curr Opin Investig Drugs 2009;10: 253-8
106. Gross GJ, Gauthier KM, Moore J, et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 2008;294:H2838-44
107. Chaudhary KR, Abukhashim M, Hwang SH, et al. Inhibition of soluble epoxide hydrolase by trans-4- [4-(3- adamantan-1-yl-ureido)-cyclohexyloxy]- benzoic acid is protective against ischemia-reperfusion injury. J Cardiovasc Pharmacol 2010;55: 67-73
108. Batchu SN, Lee SB, Qadhi RS, et al. Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br J Pharmacol 2011;162: 897-907
109. Lv X, Wan J, Yang J, et al. Cytochrome P450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 2008;596: 118-26
110. Edin ML, Wang Z, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 2011;25: 3436-47
111. Strauer BE. Myocardial oxygen consumption in chronic heart disease: role of wall stress, hypertrophy and coronary reserve. Am J Cardiol 1979;44: 730-40
112. Muthalif MM, Karzoun NA, Gaber L, et al. Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 2000;36: 604-9
113. Makita K, Takahashi K, Karara A, et al. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994;94: 2414-20
114. Jennings BL, Sahan-Firat S, Estes AM, et al. Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension 2010;56: 667-74
115. Makita K, Falck JR, Capdevila JH. Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. FASEB J 1996;10: 1456-63
116. Lee CR, Imig JD, Edin ML, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010;24: 3770-81
117. Singh H, Cheng J, Deng H, et al. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 2007;50: 123-9
118. Dreisbach AW, Japa S, Sigel A, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 2005;18: 1276-81
119. King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 2005;15: 7-13
120. Mayer B, Lieb W, Gotz A, et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006;24: 1965-70
121. Mayer B, Lieb W, Gotz A, et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005;46: 766-71
122. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007;93: 903-7
123. Thum T, Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 2002;16: 1537-49
124. Miners JO, Smith PA, Sorich MJ, et al. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 2004;44: 1-25
125. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007;1770: 489-94
126. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76: 391-6
127. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol 2002;53: 408-9
128. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356: 1667-71
129. Ma TK, Lam YY, Tan VP, et al. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther 2010;125: 249-59
130. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302: 849-57
131. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63: 519-28
132. Sorich MJ, Polasek TM, Wiese MD. Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin Pharmacol Ther 2013;94: 376-82
133. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90: 328-32
134. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002;162: 405-12
135. Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol 2011;7: 1065-82
136. Cheng JW, Frishman WH, Aronow WS. Updates on cytochrome p450-mediated cardiovascular drug interactions. Dis Mon 2010;56: 163-79
137. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180: 713-8
138. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148 e1-5
139. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363: 1909-17
140. Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011;4: 365-80
141. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94: 1140-6
142. Roten L, Schoenenberger RA, Krahenbuhl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004;38: 978-81
143. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7
144. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33: 2551-67
145. Yasar U, Bennet AM, Eliasson E, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003;13: 715-20
146. Rodenburg EM, Visser LE, Danser AH, et al. Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenet Genomics 2010;20: 426-34
147. Funk M, Endler G, Freitag R, et al. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem 2004;50: 2395-8
148. Marciante KD, Totah RA, Heckbert SR, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008;18: 535-43
149. Liu PY, Li YH, Chao TH, et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007;195: 199-206
150. Jie Z, Hong K, Jianhong T, et al. Haplotype analysis of the CYP2J2 gene associated with myocardial infarction in a Chinese Han population. Cell Biochem Funct 2010;28: 435-9
151. Cornelis MC, El-Sohemy A, Kabagambe EK, et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295: 1135-41
152. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 2004;41: 758-62
153. Fu Z, Nakayama T, Sato N, et al. A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. Mol Genet Metab 2009;96: 145-7
154. Xie X, Ma YT, Fu ZY, et al. Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction. Clin Chem Lab Med 2009;47: 347-52
155. Xiang X, Ma YT, Fu ZY, et al. Haplotype analysis of the CYP8A1 gene associated with myocardial infarction. Clin Appl Thromb Hemost 2009;15: 574-80
156. Haschke-Becher E, Kirchheiner J, Trummer O, et al. Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics 2010;11: 1359-65
157. Visser LE, van Schaik RH, Jan Danser AH, et al. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics 2007;17: 473-9
158. Kaur-Knudsen D, Bojesen SE, Nordestgaard BG. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. Pharmacogenomics J 2009;9: 327-32
159. Hoffmann MM, Bugert P, Seelhorst U, et al. The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2007;53: 539-40
160. Borgel J, Bulut D, Hanefeld C, et al. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc Disord 2008;8:41
161. Kaur-Knudsen D, Nordestgaard BG, Tybjaerg-Hansen A, et al. CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50,000 individuals. Pharmacogenet Genomics 2009;19: 685-94
162. Fu Z, Nakayama T, Sato N, et al. Haplotype-based case-control study of CYP4A11 gene and myocardial infarction. Hereditas 2012;149: 91-8
163. Hautanen A, Toivanen P, Manttari M, et al. Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation 1999;100: 2213-18
164. Hengstenberg C, Holmer SR, Mayer B, et al. Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension 2000;35: 704-9
165. Patel S, Steeds R, Channer K, et al. Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarction. Am J Hypertens 2000;13: 134-9
166. Steves CJ, Spector TD, Jackson SH. Ageing, genes, environment and epigenetics: what twin studies tell us now, and in the future. Age Ageing 2012;41: 581-6
167. Thomas F, Rudnichi A, Bacri AM, et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001;37: 1256-61
168. Force USPST. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151: 474-82
169. McNicholas WT, Bonsigore MR; Management Committee of ECAB. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007;29: 156-78
170. Hingorani AD, Liang CF, Fatibene J, et al. A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999;100: 1515-20
171. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473: 317-25
172. Lin YA, Chiang A, Lin R, et al. Methodologies for extracting functional pharmacogenomic experiments from international repository. AMIA Annu Symp Proc; 2007. p. 463-7